These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 19538112)

  • 81. Meningococcal disease and control in China: Findings and updates from the Global Meningococcal Initiative (GMI).
    Li J; Shao Z; Liu G; Bai X; Borrow R; Chen M; Guo Q; Han Y; Li Y; Taha MK; Xu X; Xu X; Zheng H
    J Infect; 2018 May; 76(5):429-437. PubMed ID: 29406154
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom.
    Auckland C; Gray S; Borrow R; Andrews N; Goldblatt D; Ramsay M; Miller E
    J Infect Dis; 2006 Dec; 194(12):1745-52. PubMed ID: 17109348
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Meningococcal serogroup A, C, W₁₃₅ and Y conjugated vaccine: a cost-effectiveness analysis in the Netherlands.
    Hepkema H; Pouwels KB; van der Ende A; Westra TA; Postma MJ
    PLoS One; 2013; 8(5):e65036. PubMed ID: 23741448
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.
    Ortega-Sanchez IR; Meltzer MI; Shepard C; Zell E; Messonnier ML; Bilukha O; Zhang X; Stephens DS; Messonnier NE;
    Clin Infect Dis; 2008 Jan; 46(1):1-13. PubMed ID: 18171206
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Systematic literature review of the impact and effectiveness of monovalent meningococcal C conjugated vaccines when used in routine immunization programs.
    Tin Tin Htar M; Jackson S; Balmer P; Serra LC; Vyse A; Slack M; Riera-Montes M; Swerdlow DL; Findlow J
    BMC Public Health; 2020 Dec; 20(1):1890. PubMed ID: 33298015
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Emergency Meningococcal ACWY Vaccination Program for Teenagers to Control Group W Meningococcal Disease, England, 2015-2016.
    Campbell H; Edelstein M; Andrews N; Borrow R; Ramsay M; Ladhani S
    Emerg Infect Dis; 2017 Jul; 23(7):1184-1187. PubMed ID: 28409739
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story.
    Miller E; Salisbury D; Ramsay M
    Vaccine; 2001 Oct; 20 Suppl 1():S58-67. PubMed ID: 11587814
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Progress toward the global control of Neisseria meningitidis: 21st century vaccines, current guidelines, and challenges for future vaccine development.
    Dretler AW; Rouphael NG; Stephens DS
    Hum Vaccin Immunother; 2018 May; 14(5):1146-1160. PubMed ID: 29543582
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Vaccines for Prevention of Group B Meningococcal Disease: Not Your Father's Vaccines.
    Harrison LH
    Am J Prev Med; 2015 Dec; 49(6 Suppl 4):S345-54. PubMed ID: 26590434
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Effectiveness of a single dose of the quadrivalent meningococcal conjugate vaccine, MenACWY-CRM, in the Korean Armed Forces.
    Im JH; Woo H; Ha BM; Lee JS; Chung MH; Jung J
    Vaccine; 2020 Jan; 38(4):730-732. PubMed ID: 31787413
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine.
    De Wals P; Deceuninck G; Boulianne N; De Serres G
    JAMA; 2004 Nov; 292(20):2491-4. PubMed ID: 15562128
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Prevention of Meningococcal Infection in the United States: Current Recommendations and Future Considerations.
    Baker CJ
    J Adolesc Health; 2016 Aug; 59(2 Suppl):S29-37. PubMed ID: 27449147
    [TBL] [Abstract][Full Text] [Related]  

  • 93. The impact of meningococcal conjugate vaccine (MenACWY-TT) on meningococcal carriage in Hajj Pilgrims returning to Turkey.
    Tezer H; Gülhan B; Simge Gişi A; Nar Ötgün S; Kanık-Yüksek S; Özkaya-Parlakay A; Kılıç S; Ünal Şahin N; Şimşek AÇ; Kara A
    Hum Vaccin Immunother; 2020 Jun; 16(6):1268-1271. PubMed ID: 31674862
    [TBL] [Abstract][Full Text] [Related]  

  • 94. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.
    McVernon J; Nolan T; Richmond P; Reynolds G; Nissen M; Lambert SB; Marshall H; Papa T; Rehm C
    Pediatr Infect Dis J; 2012 Jan; 31(1):e15-23. PubMed ID: 22094636
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Public policy for meningococcal vaccination.
    Cameron JC
    Hum Vaccin Immunother; 2018 May; 14(5):1216-1217. PubMed ID: 29194013
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Need for Optimisation of Immunisation Strategies Targeting Invasive Meningococcal Disease in the Netherlands.
    Bousema JC; Ruitenberg J
    Int J Health Policy Manag; 2015 Sep; 4(11):757-61. PubMed ID: 26673336
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Impact of routine immunization using meningococcal C conjugate vaccine on invasive meningococcal disease in British Columbia.
    Siu T; Tang W; Dawar M; Patrick DM
    Can J Public Health; 2008; 99(5):380-2. PubMed ID: 19009920
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Epidemiology and prevention of meningococcal disease: a critical appraisal of vaccine policies.
    Sáfadi MA; McIntosh ED
    Expert Rev Vaccines; 2011 Dec; 10(12):1717-30. PubMed ID: 22085175
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Priorities for research on meningococcal disease and the impact of serogroup A vaccination in the African meningitis belt.
    ; Altmann D; Aseffa A; Bash M; Basta N; Borrow R; Broome C; Caugant D; Clark T; Collard JM; Djingarey M; Goldblatt D; Greenwood B; Griffiths U; Hajjeh R; Hassan-King M; Hugonnet S; Kimball AM; LaForce M; MacLennan C; Maiden MC; Manigart O; Mayer L; Messonnier N; Moisi J; Moore K; Moto DD; Mueller J; Nascimento M; Obaro S; Ouedraogo R; Page AL; Perea W; Pluschke G; Preziosi MP; Sow S; Stephens D; Stuart J; Thomson M; Tiendrebeogo S; Trape JF; Vernet G
    Vaccine; 2013 Mar; 31(11):1453-7. PubMed ID: 23273967
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain.
    Larrauri A; Cano R; García M; Mateo Sd
    Vaccine; 2005 Jul; 23(32):4097-100. PubMed ID: 15908059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.